Author’s response to reviews

Title: Cytoreductive Surgery and Hyperthermic Intra-operative Peritoneal Chemotherapy with Cisplatin for Gastric Peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial

Authors:

Baki Topal (baki.topal@med.kuleuven.be)
Karel Demey (karel.demey@uzleuven.be)
Halit Topal (halit.topal@uzleuven.be)
Joris Jaekers (joris.jaekers@uzleuven.be)
Eric Van Cutsem (eric.vancutsem@uzleuven.be)
Vincent Vandecaveye (vincent.vandecaveye@uzleuven.be)
Xavier Sagaert (xavier.sagaert@uzleuven.be)
Hans Prenen (hans.prenen@uzleuven.be)

Version: 3 Date: 10 Oct 2017

Author’s response to reviews:

Editor Comments: Q&A

Q1. In the declarations section at the end of the manuscript, please indicate that written informed consent was obtained from the human subjects.

A1. “Written informed consent was obtained from the human subjects” has been added (Declaration section, line 43, page 16)

Q2. Please add a statement in the declarations section at the end of the manuscript indicating the source of funding for this study. If no specific funding was received for this study, please state this.

A2. “No specific funding was received for this clinical study” has been added, replacing “Not applicable”. Declaration section, line 53, page 15)
Q3. In the last line of the abstract, along with the trial registration number, please list the trial registration date. If your trial was registered after patient enrolment began, please also note this retrospective registration in the manuscript.

A3. Registration date has been added to the abstract “May 5, 2010”. This is before enrolment of first patient in the study. (Abstract section, line 58, page 3)